Comparative Pharmacology
Head-to-head clinical analysis: CEDAX versus CEFTAROLINE FOSAMIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEDAX versus CEFTAROLINE FOSAMIL.
CEDAX vs CEFTAROLINE FOSAMIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftibuten is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, thereby inhibiting peptidoglycan cross-linking and leading to cell lysis.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
400 mg orally once daily for 5-10 days.
600 mg IV every 12 hours infused over 1 hour
None Documented
None Documented
Terminal elimination half-life: 2.6-3.0 hours; prolonged in renal impairment (up to 10-15 hours in severe impairment)
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Renal: 92-96% unchanged; biliary/fecal: <5%
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic